Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/07/19 → 30/06/20 |
Funding
- AstraZeneca: A$155,100.00
Translational biomarkers of the DREAM study (a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in
- Nowak, Anna (Chief Investigator)
- Lesterhuis, Willem (Investigator 02)
- Cook, Alistair (Investigator 03)